Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health Industry Watch.
Press releases published on May 28, 2025
Aclaris Therapeutics to Participate in Two June Healthcare Conferences
GlobeNewswire
·
May 28, 2025
WAYNE, Pa., May 28, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that the Company will …
BioAdaptives® PawPa™ Regen Provides Breakthrough Stem Cell Support for Pets, Backed by Clinically Proven APBAR® Scale Improvements
GlobeNewswire
·
May 28, 2025
LAS VEGAS, May 28, 2025 (GLOBE NEWSWIRE) -- via IBN -- BioAdaptives, Inc. (OTC: BDPT), through its pets division PawPa™, a leader in premium pet wellness, proudly announces the remarkable stem cell benefits of its flagship product, Regen Dog Chews, …
Olympia Pharmaceuticals Secures $637,000 Workforce Training Grant to Boost Job Creation in Orlando
GlobeNewswire
·
May 28, 2025
ORLANDO, Fla., May 28, 2025 (GLOBE NEWSWIRE) -- Olympia Pharmaceuticals, a leading innovator in the pharmaceutical industry, is proud to announce it has secured $637,500 in workforce training funds to support the continued expansion of its sister brand, …
Marius Pharmaceuticals Receives Sixth U.S. Patent Allowance for KYZATREX® (testosterone undecanoate) CIII Capsules Extending Coverage to 2040
GlobeNewswire
·
May 28, 2025
RALEIGH, N.C., May 28, 2025 (GLOBE NEWSWIRE) -- Marius Pharmaceuticals, a pharmaceutical company focused on developing innovative therapies for testosterone deficiency, announced today that the United States Patent and Trademark Office (USPTO) for a new …
Distalmotion Gains FDA 510(k) Clearance for Cholecystectomy, Further Advancing Access to Robotics in the Outpatient Setting with its DEXTER® Robotic Surgery System
GlobeNewswire
·
May 28, 2025
Lausanne, Switzerland, May 28, 2025 (GLOBE NEWSWIRE) -- Distalmotion, the global MedTech company empowering access to the benefits of robotic surgery in more sites of care, today announced that it has received FDA 510(k) clearance for the use of its DEXTER …
Immunotherapeutic Targets for Recurrent Medulloblastoma Receives $85K Grant from Brain Cancer Canada
GlobeNewswire
·
May 28, 2025
TORONTO, May 28, 2025 (GLOBE NEWSWIRE) -- Brain Cancer Canada is proud to award $85,000 to a groundbreaking research project led by Dr. Sheila Singh and her team at McMaster University. The project titled "Lamin B Receptor (LBR) as an Immunotherapeutic …
Connect Biopharma to Present at Two Upcoming Investor Conferences in June
GlobeNewswire
·
May 28, 2025
SAN DIEGO, May 28, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a clinical-stage biopharmaceutical company focused on transforming acute and chronic care of asthma and chronic …
Flare Therapeutics to Participate in Jefferies Global Healthcare Conference
GlobeNewswire
·
May 28, 2025
CAMBRIDGE, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- Flare Therapeutics Inc. (FlareTx), a clinical-stage biotechnology company targeting transcription factors to discover precision medicines for oncology and other therapeutic areas, today announced that the …
HCVC leads kyron.bio €5.5M round to use glycan engineering for advanced drug design
GlobeNewswire
·
May 28, 2025
Paris, May 28, 2025 (GLOBE NEWSWIRE) -- One of the biggest challenges facing biologic drug developers are varying efficacy and the dangers of side effects. Biotechnology company kyron.bio today announced a €5.5 million funding round to solve these issues …
Alpha Tau to Present at Jefferies Global Healthcare Conference
GlobeNewswire
·
May 28, 2025
JERUSALEM, May 28, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced that CFO Raphi Levy will present at the …
Vittoria Biotherapeutics to Share Trials-in-Progress Presentation from Phase 1 Study of VIPER-101 at ASCO 2025 Annual Meeting
GlobeNewswire
·
May 28, 2025
PHILADELPHIA, May 28, 2025 (GLOBE NEWSWIRE) -- Vittoria Biotherapeutics Inc., a clinical-stage immunotherapy company specializing in the development of innovative therapies for hard-to-treat diseases, today announced it will present a trials-in-progress …
iTeos Therapeutics Announces Its Intention to Wind Down Operations
GlobeNewswire
·
May 28, 2025
- Board of Directors intends to cease operations - Company to focus efforts on selecting best path to deliver near-term value to shareholders - Exploring potential asset sales including EOS-984, EOS-215, and a preclinical obesity program targeting ENT1 …
SCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study
GlobeNewswire
·
May 28, 2025
First new patient dosed in Phase 3 MARIO study following the lifting of the FDA clinical hold Resumption of dosing in this study triggers a $10M milestone payment from GSK plus an additional $20M milestone due in six months; as previously disclosed GSK …
Ernexa Therapeutics Announces New Data to be Presented at ASCO Annual Meeting 2025
GlobeNewswire
·
May 28, 2025
CAMBRIDGE, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced that new data will be presented at the American Society …
Plymouth Rock Home Assurance Corporation Names Colleen Finn as Chief Marketing Officer
GlobeNewswire
·
May 28, 2025
BOSTON, May 28, 2025 (GLOBE NEWSWIRE) -- Plymouth Rock Home Assurance Corporation today announced that Colleen Finn has been appointed as Chief Marketing Officer, effective immediately. In this role, Finn will be responsible for the marketing and …
Achieve Life Sciences to Present at the Jefferies Global Healthcare Conference
GlobeNewswire
·
May 28, 2025
SEATTLE and VANCOUVER, British Columbia, May 28, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of …
Monarch Therapeutics and SNAP Biosciences, Inc., a Subsidiary of Coeptis Therapeutics Holdings Inc., Enter Licensing Agreement to Bolster SNAP-CAR NK Cell Therapy in Oncology
GlobeNewswire
·
May 28, 2025
WEXFORD, Pa. and PRINCETON, N.J., May 28, 2025 (GLOBE NEWSWIRE) -- SNAP Biosciences, Inc a majority-owned subsidiary of Coeptis Therapeutics Holdings Inc. (Nasdaq: COEP) and Monarch Therapeutics Inc., a biotechnology company pioneering next-generation …
SeaStar Medical Announces CMS Coverage for Medicare and Medicaid Eligible Patients with Cardiorenal Syndrome Awaiting LVAD in Investigational Trial of SCD Therapy
GlobeNewswire
·
May 28, 2025
Coverage marks SeaStar Medical’s second award by CMS for reimbursement of medical expenses for Medicare and Medicaid patients in a clinical trial Stands out as rare award with less than 100 clinical trials covered annually DENVER, May 28, 2025 (GLOBE …
Candel Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for CAN-2409 for the Treatment of Prostate Cancer
GlobeNewswire
·
May 28, 2025
NEEDHAM, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today …
4DMT to Participate in Upcoming Investor Conferences
GlobeNewswire
·
May 28, 2025
EMERYVILLE, Calif., May 28, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment …